Editas Medicine Inc (NASDAQ:EDIT) CEO Katrine Bosley sold 12,000 shares of the company’s stock in a transaction on Monday, December 3rd. The shares were sold at an average price of $31.92, for a total transaction of $383,040.00. Following the completion of the sale, the chief executive officer now directly owns 1,217,066 shares in the company, valued at $38,848,746.72. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Katrine Bosley also recently made the following trade(s):
- On Thursday, November 1st, Katrine Bosley sold 12,000 shares of Editas Medicine stock. The shares were sold at an average price of $26.88, for a total transaction of $322,560.00.
- On Monday, October 1st, Katrine Bosley sold 12,000 shares of Editas Medicine stock. The shares were sold at an average price of $31.02, for a total transaction of $372,240.00.
NASDAQ EDIT traded down $0.68 during mid-day trading on Friday, reaching $29.01. 10,494 shares of the stock were exchanged, compared to its average volume of 677,899. Editas Medicine Inc has a 1 year low of $22.50 and a 1 year high of $45.02. The company has a market capitalization of $1.46 billion, a PE ratio of -9.71 and a beta of 3.21. The company has a debt-to-equity ratio of 0.15, a quick ratio of 13.13 and a current ratio of 13.14.
Editas Medicine (NASDAQ:EDIT) last announced its quarterly earnings results on Wednesday, November 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.72) by $0.40. Editas Medicine had a negative net margin of 410.68% and a negative return on equity of 53.15%. The firm had revenue of $14.52 million for the quarter, compared to the consensus estimate of $9.83 million. During the same period in the prior year, the firm posted ($0.64) earnings per share. The firm’s quarterly revenue was up 131.2% compared to the same quarter last year. On average, equities analysts expect that Editas Medicine Inc will post -2.18 EPS for the current year.
Several analysts have recently commented on the stock. BidaskClub raised shares of Editas Medicine from a “hold” rating to a “buy” rating in a report on Tuesday. Guggenheim assumed coverage on shares of Editas Medicine in a report on Tuesday, October 9th. They issued a “neutral” rating on the stock. Zacks Investment Research raised shares of Editas Medicine from a “hold” rating to a “buy” rating and set a $32.00 price objective on the stock in a report on Tuesday, November 13th. Finally, Raymond James assumed coverage on shares of Editas Medicine in a report on Friday, September 21st. They issued an “outperform” rating and a $40.00 price objective on the stock. One research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $45.50.
A number of hedge funds and other institutional investors have recently made changes to their positions in EDIT. Amalgamated Bank purchased a new stake in Editas Medicine during the second quarter worth $249,000. Cornerstone Wealth Management LLC purchased a new stake in Editas Medicine during the second quarter worth $570,000. Dupont Capital Management Corp acquired a new position in Editas Medicine during the second quarter worth $342,000. Raymond James Financial Services Advisors Inc. raised its position in Editas Medicine by 91.7% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 22,066 shares of the company’s stock worth $791,000 after acquiring an additional 10,556 shares during the period. Finally, First Trust Advisors LP acquired a new position in Editas Medicine during the second quarter worth $3,362,000. 68.79% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/12/07/editas-medicine-inc-edit-ceo-katrine-bosley-sells-12000-shares.html.
About Editas Medicine
Editas Medicine, Inc operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments.
Recommended Story: Outstanding Shares
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.